Clinical Trials in Focus: Durability of Intravitreal Anti-Vascular Endothelial Growth Factor Therapies

03/28/23 • 34 min

Do you know how study designs influence the data with anti-vascular endothelial growth factor (anti-VEGF) therapies? Find out more.

Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/[ArticleID]?src=mkm_podcast_addon_989801

Do you know how study designs influence the data with anti-vascular endothelial growth factor (anti-VEGF) therapies? Find out more.

Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/[ArticleID]?src=mkm_podcast_addon_989801

Previous Episode

Safeguarding the CKD Patient With or Without Diabetes in Primary Care: Quick Questions, Rapid Replies

Did you know that SGLT2 blockade can reduce progression to ESKD by at least a decade in patients with mild-to-moderately decreased eGFR?

Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/990093?ecd=bdc_podcast_libsyn_mscpedu

Next Episode

Global Perspectives on Anti-Vascular Endothelial Growth Factor: If, When, and How to Switch

Do you reload when switching? What intervals do you extend by? How long is feasible between treatments, and how do you monitor? Learn from the experts. Credit available for this activity expires: 28/03/2024 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/990120?ecd=bdc_podcast_libsyn_mscpedu